4月15日 - ** 药物开发商Skye Bioscience SKYE.O的股价盘前上涨11.5%至1.46美元
** 该公司称， (link)，其候选药物尼马单抗在小鼠体内显示出23.5%的体重减轻效果，与礼来LLY.N的流行药物tirzepatide（以Zepbound销售）和诺和诺德NOVOb.CO的实验药物monlunabant相当。
** SKYE还表示，尼马单抗与替哌肽合用后，体重减轻了30%以上。
** 预计 2025 年第三季度末/第四季度初将获得 SKYE 肥胖症中期研究的初步数据
** 截至上一交易日收盘，股价累计下跌 53.7
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.